Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports. The brokerage ...

Richard Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions. Mr. Paolone plays a key role in advising on a range ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company ...

SAN DIEGO, CA – Daré Bioscience, Inc., a biopharmaceutical company with a current market capitalization of $26.45 million and trading at $3.04 per share, is facing potential delisting from the Nasdaq ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Entero Therapeutics has named Richard Paolone as interim chief executive.

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...